FCE 22101

Known as: FCE-22101 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1983-1994
0102019831994

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1991
1991
The pharmacokinetics of FCE 22101 were studied in rats, rabbits, Cynomolgus monkeys and dogs after intravenous administration… (More)
Is this relevant?
1989
1989
LD50 values of FCE 22101 iv were 3872 mg/kg and 4392 mg/kg in male and female mice, and 2000 mg/kg and 2201 mg/kg in male and… (More)
Is this relevant?
1989
1989
We have examined the lytic and cidal activities of FCE 22101 against bacteria exhibiting genetic tolerance (pneumococcal mutants… (More)
Is this relevant?
1989
1989
The in-vitro activities of two penems (FCE 22101 and SCH 34343) were compared to those of a carbapenem (imipenem), a monobactam… (More)
Is this relevant?
1989
1989
FCE 22101 is a new penem with broad antibacterial spectrum, excluding the pseudomonads, and has stability to many beta-lactamases… (More)
Is this relevant?
1989
1989
The in-vitro activity of a new penem FCE 22101 was evaluated in comparison with other antimicrobial agents against 966 aerobic… (More)
Is this relevant?
1988
1988
Rabbits were given benzylpenicillin, imipenem/cilastatin and a penem beta-lactam, FCE 22101, as constant intravenous infusions… (More)
Is this relevant?
1987
1987
The activity of FCE 22101 against 675 strains of anaerobic bacteria was determined by an agar dilution method. Its activity was… (More)
Is this relevant?
1985
1985
FCE 22101 is a penem antibiotic which inhibits the majority of Enterobacteriaceae, Haemophilus influenzae, and Neisseria… (More)
Is this relevant?
1983
1983
The in vitro activity of FCE 22101, a new semisynthetic penem derivative, was compared with that of ceftriaxone, moxalactam… (More)
  • table 1
  • table 1
  • figure 1
  • table 3
Is this relevant?